Advertisement
Screener

Pluri Inc. (PLUR) Segment Reporting Other Item Amount

2.8 / 5 stars · 68/120 Roast Me

Pluri Inc. Segment Reporting Other Item Amount

Pluri Inc. (PLUR) reported Segment Reporting Other Item Amount of $9.59 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-10.

Financial Statements › Notes › Segment Reporting

us-gaap:SegmentReportingOtherItemAmount · last filed 2026-09-10

  • Pluri Inc. segment reporting other item amount for the quarter ending 2026-06-30 was $2.67M, a 24.27% decline year-over-year.
  • Pluri Inc. segment reporting other item amount for the quarter ending 2026-03-31 was $2.19M, a 18.21% decline year-over-year.
  • Pluri Inc. segment reporting other item amount for the quarter ending 2025-12-31 was $2.66M.
  • Pluri Inc. segment reporting other item amount for the quarter ending 2025-09-30 was $2.51M, a 11.48% decline year-over-year.
  • Pluri Inc. segment reporting other item amount for fiscal 2026 was $9.59M, a 21.66% increase from fiscal 2025.
  • Pluri Inc. segment reporting other item amount for fiscal 2025 was $7.88M, a 5.06% increase from fiscal 2024.
  • Pluri Inc. segment reporting other item amount for fiscal 2024 was $7.50M.
Period endSegment Reporting Other Item Amount 3 monthSegment Reporting Other Item Amount 6 monthSegment Reporting Other Item Amount 9 monthSegment Reporting Other Item Amount 12 monthSegment Reporting Other Item Amount 12 month as first filed
2026-06-30$2.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-10
$4.86M
derived: sum of 2 quarters · filed 2026-09-10
$7.52M
derived: sum of 3 quarters · filed 2026-09-10
$9.59M
10-K · filed 2026-09-10
2026-03-31$2.19M
10-Q · filed 2026-05-14
$4.85M
derived: sum of 2 quarters · filed 2026-05-14
$6.92M
10-Q · filed 2026-05-14
$10.88M
derived: sum of 4 quarters · filed 2026-09-10
2025-12-31$2.66M
10-Q · filed 2026-02-12
$4.73M
10-Q · filed 2026-02-12
$8.69M
derived: sum of 3 quarters · filed 2026-09-10
$11.37M
derived: sum of 4 quarters · filed 2026-09-10
2025-09-30$2.51M
10-Q · filed 2025-11-12
$6.03M
derived: sum of 2 quarters · filed 2026-09-10
$8.71M
derived: sum of 3 quarters · filed 2026-09-10
$8.20M
derived: sum of 4 quarters · filed 2026-09-10
2025-06-30$3.53M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-10
$6.21M
derived: sum of 2 quarters · filed 2026-09-10
$5.70M
derived: sum of 3 quarters · filed 2026-09-10
$7.88M
10-K · filed 2026-09-10
$9.80M
10-K · filed 2025-09-17
2025-03-31$2.68M
10-Q · filed 2026-05-14
$2.17M
derived: sum of 2 quarters · filed 2026-05-14
$4.36M
10-Q · filed 2026-05-14
2024-12-31-$509.00K
10-Q · filed 2026-02-12
$1.68M
10-Q · filed 2026-02-12
2024-09-30$2.83M
10-Q · filed 2025-11-12
2024-06-30$7.50M
10-K · filed 2025-09-17

Similar stocks

Stock NameCountryMarket CapPE Ratio
INTENSITY THERAPEUTICS, INC. (INTS)United States$0.013B-1.08
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)United States$0.013B-1.05
Passage BIO, Inc. (PASG)United States$0.015B-0.43
IN8BIO, INC. (INAB)United States$0.012B-0.76
DYADIC INTERNATIONAL INC (DYAI)United States$0.016B
BioCardia, Inc. (BCDA)United States$0.016B
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
Jasper Therapeutics, Inc. (JSPR)United States$0.020B-0.37
CERO THERAPEUTICS HOLDINGS, INC. (CERO)United States$0.007B